| Finding Agency | Project Title | Approved Fund | Duration |
| DST SERB-CRG | Therapeutic potential of endogenous peptides in hypertension | 36 Lakhs | 2021-2024 |
| ICMR | Role of novel endogenous peptides in cardiometabolic disorders | 29 Lakhs | 2021-2024 |
| ICMR | Therapeutic potential of novel MAD2 inhibitors in ovarian cancer | 35 Lakhs | 2022-2025 |
| ISSAR Pharmaceuticals | Pre-Clinical Efficacy Evaluation of synthetic Peptides For the Treatment of Inflammatory Bowel Disease & Sepsis | 29 Lakhs | 2020-2023 |
| Department of Science and Technology (DST) and SERB Under Young Scientist Scheme) | Role of double stranded RNA dependent protein kinase (PKR) in hypertension: Mechanism and prevention | 27 Lakhs | 2015-2018 |
| CSIR | Pharmacological evaluation of novel double stranded RNA dependent protein kinase (PKR) inhibitors for diabetic cardiomyopathy”. | 24 Lakhs | 2015-2018 |
| BITS (Under additional Competitive grant) | Evaluation of novel pharmacological agents targeted at methylglyoxal in diabetic cardiomyopathy | 10 Lakhs | 2015-2017 |
| UGC | Evaluation of pharmacological agents targeted at double stranded RNA dependent protein kinase (PKR) in type 2 diabetes mellitus | 6 Lakhs | 2014-2016 |
| BITS (Research Initiation Grant) | Role of methyglyoxal in diabetic cardiomyopathy | 2 Lakhs | 2014-2016 |
1. Mangali S, Bhat A, Jadhav K, Kalra J, Sriram D, Vamsi Krishna Venuganti V, Dhar A. Upregulation of PKR pathway mediates glucolipotoxicity induced diabetic cardiomyopathy in vivo in wistar rats and in vitro in cultured cardiomyocytes. Biochem Pharmacol. 2020 Jul;177:113948.
2. Kalra J, Mangali S, Bhat A, Jadhav K B, Dhar A. Selective Inhibition of PKR Improves Vascular Inflammation and Remodelling in High Fructose Treated Primary Vascular Smooth Muscle Cells. Biochim Biophys Acta Mol Basis Dis. 2020 Mar 1;1866(3):165606.
3. Kalra J, Mangali SB, Dasari D, Bhat A, Goyal S, Dhar I, Sriram D, Dhar A. SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy. Fundam Clin Pharmacol. 2019 Nov 7. doi: 10.1111/fcp.12516.
4. Mangali S, Bhat A, Udumula MP, Dhar I, Sriram D, Dhar A. Inhibition of protein kinase R protects against palmitic acid-induced inflammation, oxidative stress, and apoptosis through the JNK/NF-kB/NLRP3 pathway in cultured H9C2 cardiomyocytes. J Cell Biochem. 2019;120(3):3651-3663
5. Kalra J, Mangali SB, Bhat A, Dhar I, Udumula MP, Dhar A.Imoxin attenuates high fructose induced oxidative stress and apoptosis in renal epithelial cell via downregulation of PKR Pathway.Fundam Clin Pharmacol. 2018 Feb 11.
6. Udumula MP, Babu MS, Bhat A, Dhar I, Sriram D, Dhar A.High glucose impairs insulin signaling via activation of PKR pathway in L6 muscle cells.Biochem Biophys Res Commun. 2017 May 6;486(3):645-651.
7. Kalra J, Dhar A.Double-stranded RNA-dependent protein kinase signalling and paradigms of cardiometabolic syndrome.Fundam Clin Pharmacol. 2017 Jun;31(3):265-279.
8. Dhar A.The Role of PKR as a Potential Target for Treating Cardiovascular Diseases.Curr Cardiol Rev. 2017;13(1):28-31.
9. Dhar A, Udumula MP, Medapi B , Bhat A , Dhar I, Malapati P, Babu SB, Kalra J, Sriram D, Desai KM. International Journal of Cardiology (Accepted for publication). (Corresponding author) (Impact factor: 4.6)
10. Dhar A. The role of PKR as a potential target for treating cardiovascular diseases. Curr Cardiol Rev. 2016 May 26.
11. Udumula MP, Medapi B, Dhar I, Bhat A, Desai K, Sriram D, Dhar A. The Small Molecule Indirubin-3'-Oxime Inhibits Protein Kinase R: Antiapoptotic and Antioxidant Effect in Rat Cardiac Myocytes.Pharmacology. 2016;97(1-2):25-30. (Corresponding author) (Impact factor: 1.9)
12. Dhar A, Dhar I, Bhat A, Desai KM. Alagebrium attenuates methylglyoxal induced oxidative stress and AGE formation in H9C2 cardiac myocytes. Life Sci. 2016 Feb 1;146:8-14. (Corresponding author) (Impact factor: 2.9)
13. Prasad K, Dhar A. Flaxseed and Diabetes. Curr Pharm Des. 2016;22(2):141-4. (Impact factor: 3.6)
14. Bahal R, Lakhani P, Bhat A, Kondiparthi L, Dhar I, Desai K, Dhar A*. Protein Kinase R and the metabolic syndrome. Journal of Cellular Biotechnology, vol. 1, no. 1, 2015, pp. 53-61. (Corresponding author)
15. Dhar A*, Reddy P, Bhat A, Dhar I, Desai K. Double stranded RNA dependent Protein kinase and type 2 diabetes. Pharmacy and Pharmacology International Journal. P2015, 2(2): 00015. (Corresponding author)
16. Pham Nf, Dhar Af, Khalaj S, Desai K, Taghibiglou C. Down regulation of brain cellular prion protein in an animal model of insulin resistance: Possible implication in increased prevalence of stroke in pre-diabetics/diabetic. Biochem Biophys Res Commun. 2014;448:151-156. (f-first two authors equal contribution)(Impact factor: 2.5)
17. Dhar I, Dhar A, Wu L, Desai,K. Methylglyoxal, a reactive glucose metabolite, increases renin angiotensin aldosterone and blood pressure in male sprague-dawley rats. Am J Hypertens. 2014, 27, 308-316 (Impact factor: 3.6)
18. Dhar I, Dhar A, Wu L, Desai K. Increased methylglyoxal formation with upregulation of renin angiotensin system in fructose fed Sprague Dawley rats. PLoS One. 2013, 9, e74212. (Impact factor: 3.7)
19. Dhar I, Dhar A, Wu L, Desai K. "D-arginine attenuates methylglyoxal- and highglucose-induced endothelial dysfunction and oxidative stress by an eNOS-independent mechanism. J Pharmacol Exp Ther. 2012, 342,196-204. (Impact factor: 3.8)
20. Untereiner A, Dhar, A, Liu J, Wu L. Increased renal methylglyoxal formation with down-regulation of PGC-1α-FBPase pathway in cystathionine γ-lyase knockout mice. PLOS One. 2011, 6, e29592. (Impact factor: 3.7)
21. Dhar A Dhar I, Jiang, B, Desai, K, Wu L. Chronic methylglyoxal administration by minipump induces pancreatic beta cell dysfunction and type 2 diabetes in Sprague-Dawley rats. Diabetes. 2011, 60, 899-908. (Impact factor: 8.8)
22. Dhar A, Dhar I, Desai K, Wu L. Methylglyoxal, a glucose metabolite induces endothelial dysfunction: Implications for hyperglycemia. Br J Pharmacol. 2010, 161, 1843-1856. (Impact factor: 5.06)
23. Dhar A, Desai K, Wu L. Alagebrium attenuates acute methylglyoxal induces glucose intolerance in Sprague-Dawley rats. Br J Pharmacol. 2010, 159, 166-175. (Impact factor: 5.06)
24. Desai K, Chang T, Wang H, Banigesh A, Dhar A, Liu J, Untereiner A, Wu L. Oxidative stress and ageing: Is methylglyoxal the hidden enemy? Can J Physiol Pharmacol. 2010, 88, 273-284. (Impact factor: 3.7)
25. Dhar A, Desai K, Liu J, Wu L. Methyglyoxal, protein binding and biological samples: Are we getting the true measure? J Chromatog B. 2009, 877, 1093-10100. (Impact factor: 2.9)
26. Dhar A, Desai K, Kazachmov M, Yu P, Wu L. Methylglyoxal production in vascular smooth cells from different metabolic precursors. Metabolism Clin Exptl. 2008, 57, 1211-1220. (Impact factor: 3.096)
27. Sharma SS, Dhar A, Kaundal K. FeTPPS protects against global cerebral ischemic-reperfusion injury in gerbils, Pharmacol Res. 2007, 55, 335-342. (Impact factor: 4.4)
28. Roy S, Khanna V, Mittra S, Dhar A, Singh S, Mahajan DC, Priyadarsiny P, Davis JA, Sattigeri J, Saini KS, Bansal V. Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: Preclinical efficacy and safety in db/db mice. Life Sci. 2007, 81, 72-79. (Impact factor: 2.55)
29. Dhar A, Sharma S S, Kaundal K. Neuroprotective effects of FeTMPyP: a peroxynitrite decomposition catalyst in global cerebral ischemia model in gerbils. Pharmacol Res. 2006, 5, 311-316. (Impact factor: 4.4)
30. Sharma SS, Dhar A, Kaundal RK.FeTPPS protects against global cerebral ischemic-reperfusion injury in gerbils.Pharmacol Res. 2007 Apr;55(4):335-42.